Analyzing R&D Budgets: Amgen Inc. vs Catalyst Pharmaceuticals, Inc.

Biotech R&D: Amgen vs Catalyst's Decade of Innovation

__timestampAmgen Inc.Catalyst Pharmaceuticals, Inc.
Wednesday, January 1, 2014429700000010117774
Thursday, January 1, 2015407000000011801342
Friday, January 1, 2016384000000011369941
Sunday, January 1, 2017356200000011375237
Monday, January 1, 2018373700000019919204
Tuesday, January 1, 2019411600000018842752
Wednesday, January 1, 2020420700000016496715
Friday, January 1, 2021481900000016936000
Saturday, January 1, 2022443400000019789000
Sunday, January 1, 2023478400000093150000
Monday, January 1, 20245964000000
Loading chart...

Cracking the code

A Decade of R&D: Amgen Inc. vs Catalyst Pharmaceuticals, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Amgen Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. Amgen, a titan in the biotech industry, consistently allocated substantial resources, with R&D expenses peaking at nearly $4.8 billion in 2021. This represents a steady growth of approximately 35% from 2014. In stark contrast, Catalyst Pharmaceuticals, a smaller player, saw its R&D budget grow by over 800% from 2014 to 2023, reaching $93 million. This dramatic increase underscores Catalyst's commitment to expanding its research capabilities. The data reveals a fascinating narrative of scale and strategy, highlighting how different companies prioritize innovation. As the biotech sector continues to grow, these investments will likely shape the future of healthcare and treatment options worldwide.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025